Daniela Angela Covino

Daniela Angela Covino

Auto-generated profile, based on publicly available information

Daniela Angela Covino

Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2015 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
DCDaniela Angela Covino
Daniela Angela Covino
Michela SabbatucciMichela Sabbatucci
Michela Sabbatucci
LFLaura Fantuzzi
Laura Fantuzzi
The identification of chemokine receptors as necessary co-receptors for HIV entry into target cells represented a breakthrough in the understanding of the pathogenesis of this viral infection. Since this initial discovery, it was unraveled that chemokines, in addition to their role in blocking viral entry by binding to co-receptors, have other functions in HIV pathogenesis. Indeed, chemokines can either inhibit or enhance HIV replication, and these effects may involve both entry and post-entry events of the viral life cycle. Depending on the balance of their negative versus positive effects on HIV replication and spreading, chemokines contribute to different outcomes of HIV pathogenesis. CCL2 is unique among the chemokines in that mostly enhancing effects on viral replication and pathogenesis have been reported. Either HIV infection itself or exposure to viral products can induce the expression of this chemokine and of its receptor CCR2, and high levels of CCL2/CCR2 are indeed found in HIV-infected subjects. The CCL2/CCR2 axis is tightly linked to the high level of immune activation and inflammation that is the hallmark of HIV infection even in patients undergoing antiretroviral therapy. In addition, more direct effects of CCL2 on HIV replication are becoming apparent. Thus, modulation of CCL2/CCR2-driven effects may have significant impact on HIV disease progression. In this review, we will discuss the complex interaction between CCL2/CCR2 and HIV and the emerging therapeutic approaches based on the inhibition of this axis.

19 September 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
Michela SabbatucciMichela Sabbatucci
Michela Sabbatucci
AMAlessandra Mallano
Alessandra Mallano
CPCristina Purificato
Cristina Purificato
DCDaniela Angela Covino
Daniela Angela Covino
MFMaurizio Federico
Maurizio Federico
LFLaura Fantuzzi
Laura Fantuzzi